Skip to main content

Advertisement

Table 3 Genotype frequencies and association tests of rs738409 in PNPLA3 in patients with NAFLD and control subjects

From: Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease

  Genotype CC/CG/GG Risk allele (G) frequency Pvalue (additive model) OR (95% CI) HWE
    Unadjusted Adjusted for age and gender Adjusted for age, gender and BMI Heterogyotes Homogyotes Additive model * Pvalue
NAFLD vs. control
NAFLD 45/111/97 0.60 9.4 × 10-10 1.9 × 10-8 0.00087 1.46 (0.98 - 2.16) 3.63 (2.36 - 5.57) 1.73 (1.25 - 2.38) 0.18
Control 175/296/104 0.44        0.28
NASH vs. control
NASH 26/85/78 0.64 1.8 × 10-11 5.7 × 10-10 0.00082 1.93 (1.20 - 3.12) 5.05 (3.04 - 8.37) 2.00 (1.33 - 3.00) 0.71
Control 175/296/104 0.44        0.28
NASH vs. simple steatosis
NASH 26/85/78 0.64 0.0083 0.010 0.021 2.39 (1.14 - 4.99) 3.00 (1.38 - 6.51) 1.65 (1.08 - 2.51) 0.71
Simple steatosis 19/26/19 0.50        0.13
Simple steatosis vs. control
Simple steatosis 19/26/19 0.50 0.18 0.24 0.16 0.81 (0.44 - 1.50) 1.68 (0.85 - 3.32) 1.37 (0.88 - 2.14) 0.13
Control 175/296/104 0.44        0.28
  1. CI, confidence interval; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; HWE, Hardy-Weinberg equilibrium; OR, odds ratio. * The OR was adjusted simultaneously for age, gender, and BMI using the additive model.